# EDGAR Filing Document

**Accession Number:** 0001563577
**File Stem:** 0001193125-26-216710
**Filing Date:** 2026-5
**Character Count:** 7959
**Document Hash:** 484d8a8e588270440e44fd8836bb6c72
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-216710.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001193125-26-216710

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260508

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Galera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001563577
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461454898
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39114
- **FILM NUMBER:** 26963042

**BUSINESS ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE
- **STREET 2:** SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 610-725-1500

**MAIL ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE
- **STREET 2:** SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of report (Date of earliest event reported): May 8, 2026

## GALERA THERAPEUTICS, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39114** | **46-1454898** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(Commission**<br>**File Number)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

#### 101 Lindenwood Drive, Suite 225

#### Malvern, PA 19355

#### (Address of principal executive offices) (Zip Code)
(610) 725-1500

#### (Registrant's telephone number, include area code)

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common Stock, $0.001 par value per share | GRTX | OTCQB Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

At the combined 2025 and 2026 Annual Meeting of Stockholders (the "**Annual Meeting**") of Galera Therapeutics, Inc. (the "**Company**") held on May 8, 2026, the Company's stockholders (i) elected (A) one Class III director to the board of directors of the Company (the "**Board**"), to serve until the Company's 2028 annual meeting of stockholders and until his successor is duly elected and qualified, and (B) two Class I directors to the Board, each to serve until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified; (ii) ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; (iii) approved the compensation paid to the Company's named executive officers ("**Say-on-Pay**"); (iv) approved a frequency of every "one year" for holding future Say-on-Pay votes; (v) approved an amendment to the Company's Restated Certificate of Incorporation (the "**Charter**") to increase the number of authorized shares of the Company's common stock from 200 million shares to 400 million shares; (vi) approved an amendment to the Charter to permit stockholders to act by written consent in lieu of a meeting; and (vii) approved an amendment to the Charter that would effect a reverse stock split at a ratio between 1:75 and 1:200, if and when determined by the Board.

The results of the voting at the Annual Meeting are shown below:

#### Proposal 1—Election of Directors:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(a) Class III Director* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Nominee** | **For** | **For** | **Withhold** | **Withhold** | **Broker Non-Votes** | **Broker Non-Votes** |
| J. Mel Sorensen, M.D. |  | 98328390 |  | 14552053 |  | 10877949 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(b) Class I Directors* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Nominees** | **For** | **For** | **Withhold** | **Withhold** | **Broker Non-Votes** | **Broker Non-Votes** |
| Nancy Chang, Ph.D. |  | 110531164 |  | 2349279 |  | 10877949 |
| Michael Friedman |  | 110523157 |  | 2357286 |  | 10877949 |

---

#### Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 121742195 | 1961191 | 55006 |

---

#### Proposal 3—Say-on-Pay Vote:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 108167385 | 3690210 | 1022848 | 10877949 |

---

#### Proposal 4—Advisory Vote on Frequency of Future Say-On-Pay Votes:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1 Year** | **2 Years** | **3 Years** | **Abstentions** | **Broker Non-Votes** |
| 108127837 | 64666 | 3611866 | 1076074 | 10877949 |

---

------

The Board had previously approved a frequency of every one year for future Say-on-Pay votes, subject to the same frequency receiving the highest number of votes from stockholders at the Annual Meeting. Accordingly, the Company will include an advisory vote to approve executive compensation on an annual basis until the next required vote on the frequency of future Say-on-Pay votes.

#### Proposal 5—Approval of Charter Amendment to Increase Authorized Capital Stock:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 120916020 | 2745505 | 96867 |

---

#### Proposal 6—Approval of Charter Amendment to Provide Written Consent Right:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 112456777 | 417500 | 6166 | 10877949 |

---

#### Proposal 7—Approval of Charter Amendment to Effect a Reverse Stock Split:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 121087262 | 2639613 | 31517 |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | GALERA THERAPEUTICS, INC. | GALERA THERAPEUTICS, INC. |
| Date: May 11, 2026 | By: | /s/ J. Mel Sorensen, M.D. |
|  |  | J. Mel Sorensen, M.D. |
|  |  | President and Chief Executive Officer |

---